In Vitro Interaction of Binuclear Copper Complexes with Liver Drug-Metabolizing Cytochromes P450

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61389030%3A_____%2F24%3A00600983" target="_blank" >RIV/61389030:_____/24:00600983 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/61989592:15110/24:73626647 RIV/61989592:15310/24:73626647

Výsledek na webu

<a href="https://doi.org/10.3390/ph17091194" target="_blank" >https://doi.org/10.3390/ph17091194</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3390/ph17091194" target="_blank" >10.3390/ph17091194</a>

Jazyk výsledku

angličtina

Název v původním jazyce

In Vitro Interaction of Binuclear Copper Complexes with Liver Drug-Metabolizing Cytochromes P450

Popis výsledku v původním jazyce

Two copper(II) mixed ligand complexes with dicarboxylate bridges were prepared and studied, namely [Cu-2(mu-fu)(pmdien)(2)(H2O)(2)](ClO4)(2) (complex No. 5) and [Cu-2(mu-dtdp)(pmdien)(2)(H2O)(2)](ClO4)(2) (complex No. 6), where H(2)fu = fumaric acid, pmdien = N,N,N ',N '',N '' pentamethyldiethylenetriamine, and H(2)dtdp = 3,3 '-dithiodipropionic acid. The copper atoms are coordinated in the same mode by the tridentate pmdien ligand and oxygen of water molecules, and they only differ in the dicarboxylate bridge. This work is focused on the study of the inhibitory effect of these potential antimicrobial drugs on the activity of the most important human liver drug-metabolizing enzymes, cytochromes P450 (CYP), especially their forms CYP2C8, CYP2C19, and CYP3A4. The obtained results allow us to estimate the probability of potential drug interactions with simultaneously administrated drugs that are metabolized by these CYP enzymes. In conclusion, the presence of adverse effects due to drug-drug interactions with concomitantly used drugs cannot be excluded, and hence, topical application may be recommended as a relatively safe approach.

Název v anglickém jazyce

In Vitro Interaction of Binuclear Copper Complexes with Liver Drug-Metabolizing Cytochromes P450

Popis výsledku anglicky

Two copper(II) mixed ligand complexes with dicarboxylate bridges were prepared and studied, namely [Cu-2(mu-fu)(pmdien)(2)(H2O)(2)](ClO4)(2) (complex No. 5) and [Cu-2(mu-dtdp)(pmdien)(2)(H2O)(2)](ClO4)(2) (complex No. 6), where H(2)fu = fumaric acid, pmdien = N,N,N ',N '',N '' pentamethyldiethylenetriamine, and H(2)dtdp = 3,3 '-dithiodipropionic acid. The copper atoms are coordinated in the same mode by the tridentate pmdien ligand and oxygen of water molecules, and they only differ in the dicarboxylate bridge. This work is focused on the study of the inhibitory effect of these potential antimicrobial drugs on the activity of the most important human liver drug-metabolizing enzymes, cytochromes P450 (CYP), especially their forms CYP2C8, CYP2C19, and CYP3A4. The obtained results allow us to estimate the probability of potential drug interactions with simultaneously administrated drugs that are metabolized by these CYP enzymes. In conclusion, the presence of adverse effects due to drug-drug interactions with concomitantly used drugs cannot be excluded, and hence, topical application may be recommended as a relatively safe approach.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30107 - Medicinal chemistry

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Pharmaceuticals

ISSN

1424-8247

e-ISSN

1424-8247

Svazek periodika

17

Číslo periodika v rámci svazku

9

Stát vydavatele periodika

CH - Švýcarská konfederace

Počet stran výsledku

11

Strana od-do

1194

Kód UT WoS článku

001326108100001

EID výsledku v databázi Scopus

2-s2.0-85205108057